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Abstract
Virotherapy using oncolytic vaccinia virus (VACV) strains is one promising new strategy for canine cancer therapy. In this
study we describe the establishment of an in vivo model of canine soft tissue sarcoma (CSTS) using the new isolated cell line
STSA-1 and the analysis of the virus-mediated oncolytic and immunological effects of two different Lister VACV LIVP1.1.1
and GLV-1h68 strains against CSTS. Cell culture data demonstrated that both tested VACV strains efficiently infected and
destroyed cells of the canine soft tissue sarcoma line STSA-1. In addition, in our new canine sarcoma tumor xenograft mouse
model, systemic administration of LIVP1.1.1 or GLV-1h68 viruses led to significant inhibition of tumor growth compared to
control mice. Furthermore, LIVP1.1.1 mediated therapy resulted in almost complete tumor regression and resulted in long-
term survival of sarcoma-bearing mice. The replication of the tested VACV strains in tumor tissues led to strong oncolytic
effects accompanied by an intense intratumoral infiltration of host immune cells, mainly neutrophils. These findings suggest
that the direct viral oncolysis of tumor cells and the virus-dependent activation of tumor-associated host immune cells
could be crucial parts of anti-tumor mechanism in STSA-1 xenografts. In summary, the data showed that both tested
vaccinia virus strains and especially LIVP1.1.1 have great potential for effective treatment of CSTS.
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Introduction
Canine soft tissue sarcomas (CSTSs) typically arise in middle-
age to old dogs and are a diverse group of cancers that collectively
comprise 7% of cutaneous and 15% of subcutaneous canine
cancers [1–5]. The annual incidence of CSTSs is about 35 per
100,000 dogs at risk [4]. Although CSTSs have similarity in
histological features and clinical behavior, these tumors are
phenotypically diverse with frequently controversial histogenesis
[6]. They include fibrosarcomas, myxosarcomas, liposarcomas,
perivascular wall tumors, peripheral nerve sheath tumors (PNST),
pleomorphic sarcoma, mesenchymoma, leiomyosarcoma and
rhabdomyosarcomas [1,2,6,7]. CSTSs are graded as low (grade
I), intermediate (grade II) and high (grade III) grade tumors based
on mitotic index, tumor necrosis, and degree of differentiation
[6,8,9]. Histological grading is considered a prognostic indicator
for CSTSs [10]. Grade I soft tissue sarcomas tend to be locally
invasive but rarely metastasize, whereas grade II tumors are
invasive and have a 7–33% chance of spreading to the lung or
regional lymph nodes [6]. Grade III tumors are uncommon and
are thought to have a higher rate of recurrence and metastasis [6].
Treatment routines consist of wide surgical excision, radiation
therapy and adjuvant chemotherapy. Despite progress in the
diagnosis and treatment of CSTSs, the prognosis for canine
patients with high-grade soft tissue sarcoma is poor due to the high
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37239probability of metastasis [1,2,11]. Therefore, the development of
new therapies for CSTSs is very important. One of the most
promising novel cancer therapies is oncolytic virotherapy. This
method is based on the capacity of oncolytic viruses (OVs) to
eliminate malignancies by direct targeting and lysis of cancer cells.
Currently several OV platforms (herpes simplex virus, vaccinia
virus, Seneca valley virus and reovirus) are in or entering Phase III
human clinical trials. In addition, in China the oncolytic
adenovirus H101 has been approved in the treatment of human
patients with head and neck cancer since 2005 [12].
In this study, we analyzed the therapeutic potential of two
different oncolytic vaccinia virus strains against CSTSs in a
preclinical mouse model. Two tested viruses, namely GLV-1h68
and LIVP1.1.1 contain an inactive thymidine kinase (tk) gene and
show inherently more tumor-selective replication than vaccinia
virus WR strain [13,14]. LIVP1.1.1 was isolated from a wild type
stock of Lister strain of vaccinia virus (Lister strain, Institute of
Viral Preparations, Moscow, Russia). We have chosen LIVP1.1.1
for this study, since it was less virulent compared to other Lister
strain isolates (Chen et al manuscript in preparation).
The virus strain GLV-1h68 was engineered by inserting 3
expression cassettes encoding a) Renilla luciferase-green fluorescent
protein (Ruc-GFP) fusion protein into the F14.5L locus, b) ß-
galactosidase into the thymidine kinase (tk) locus, and c) ß-
glucuronidase into the hemagglutinin locus from the genome of
the LIVP strain [13]. GLV-1h68 showed potent anticancer
efficacy in many different human tumor xenograft models,
including human breast cancer [13], anaplastic thyroid carcinoma
[15,16], malignant pleural mesothelioma [17], pancreatic tumor
[18], hepatocellular carcinoma (HCC) [19], prostate carcinoma
[20], and squamous cell carcinoma [21]. Moreover, results of a
Phase 1 study of intravenous administration of GL-ONC1 (GLV-
1h68) vaccinia virus in human patients with advanced solid cancer
demonstrated safety, preliminary evidence of anticancer activity
and virus replication (http://www.ncri.org.uk/ncriconference/
2010abstracts/abstracts/C122.htm).
In addition, we have already demonstrated the therapeutic
effect of GLV-1h68 against canine mammary adenoma and
carcinoma using ZMTH3 and MTH52c cells, respectively, in
xenograft models [22,23].
Here, we describe the establishment of an in vivo model of CSTS
using a newly isolated cell line derived from a canine patient with a
low grade II soft tissue sarcoma. The development of this new
xenograft model was necessary, because very few canine soft tissue
sarcoma cell lines exist [24]. In addition, we analyzed the virus-
mediated oncolytic and immunological effects of two different
Lister VACV strains against CSTS by using fluorescence imaging,
immunohistochemistry and flow cytometry.
Materials and Methods
Ethics statement
All animal experiments were carried out in accordance with
protocols approved by the Institutional Animal Care and Use
Committee of Explora Biolabs (San Diego, CA) and/or the
government of Unterfranken, Germany (permit number: 55.2-
2531.01-17/08).
Donor
The cell line STSA-1 was derived from a tumor of a seven-year-
old, male, neutered golden retriever dog that presented with a
firm, painful, erythematous mass on the left forelimb. The mass
was surgically debulked with excision of the deep digital flexor and
flexor carpi muscles as they were extensively infiltrated by the
tumor. Histopathology performed on the surgically excised mass
was described in Results. The patient underwent full course
Figure 1. Imaging of STSA-1 tumors (A, C) and canine soft tissue sarcoma cells (B, D). (A) Histologic section of a canine soft tissue sarcoma
from the limb of a golden retriever dog, hematoxylin and eosin stain (H&E,6200 magnification). (B) Cytology of canine soft tissue sarcoma cells STSA-
1 isolated from a subcutaneous mass on a golden retriever dog, Wright-Giemsa stain (61000 magnification). (C) Canine soft tissue sarcoma STSA-1
xenograft, right flank, athymic nude mouse (H&E,6200 magnification). (D) Transmitted light microscopy of uninfected STSA-1 cells in MEM-C culture
(6100 magnification).
doi:10.1371/journal.pone.0037239.g001
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radiographs and abdominal ultrasound showed no evidence of
metastasis, but radiographs of the left front limb revealed severe
lysis of the distal ulna, caudal distal radius, and carpal bones. A
fine needle aspirate of an enlarged left prescapular lymph node
was diagnosed by cytology as metastatic meschenchymal neopla-
sia. At this time, the limb was amputated and enlarged lymph
nodes were removed. Cells were isolated aseptically from the mass
for culture in the laboratory as described in Materials and
Methods. Cytochemical staining and genetic analysis of the
isolated canine cells were performed as described below.
The entire limb as well as axillary and prescapular lymph nodes
were formalin-fixed and submitted for histology. Histologically,
the lesion was consistent with a soft tissue sarcoma of intermediate
grade with vascular invasion, infiltration of the tumor cells into the
bone marrow cavity and metastases to draining lymph nodes.
Over the next two months, the canine patient received chemo-
therapy, but regrowth of the mass was observed and the dog was
euthanized due to side effects caused by the chemotherapeutics.
Cell culture
African green monkey kidney fibroblasts (CV-1) were obtained
from the American Type Culture Collection (ATCC). CV-1 cells
were cultured in DMEM supplemented with antibiotic-solution
(100 U/ml penicillin G, 100 units/ml streptomycin) and 10% fetal
bovine serum (FBS; Invitrogen GmbH, Karlsruhe, Germany).
STSA-1 cells described in this paper were isolated from
surgically excised spontaneous canine tumor removed from a
patient at the University of Illinois Veterinary Teaching Hospital.
Fat and necrotic tissue were removed from an unfixed section of
the tumor. The mass was then minced into one millimeter cubes,
placed in a 25 cm
2 cell culture flask (Nunc, Wiesbaden, Germany)
and left to adhere for 10 min at room temperature with
subsequent addition of minimum essential medium with Earle’s
salts supplemented with 2 mM glutamine, 50 U/mL penicillin G,
50 mg/mL streptomycin, 1 mM sodium pyruvate, 0.1 mM non-
essential amino acids (MEM-C), and 10% FBS, then incubated at
37uC, 5% CO2, and 100% humidity. Trypsinization and passage
of the cultured cells was performed when cells covered approx-
imately 80% of the flask surface or sooner if tissue explants were
decaying. Once a primary culture was established, it was
maintained in MEM-C with 10% FBS and incubated as above.
To analyze cell type using cytochemical and immunocytochem-
ical stains, primary cells were grown in 35 mm diameter plates
(Nunc) as described above. Then cells were trypsinized, collected
in MEM-C with 10% FBS and pelleted by centrifugation at 4006g
for 5 min. The cellular pellets were suspended in 1 mL phosphate-
buffered saline (PBS) from which 100 mL aliquots of cells were
Table 1. Staining characteristics of cells isolated from a spontaneous tumor growth on a golden retriever dog.
Cell Name Histopathological Diagnosis Positive Cytochemical Staining Negative Cytochemical Staining
STSA-1 Soft tissue sarcoma Vimentin Alkaline phosphatase CD18 Cytokeratin
doi:10.1371/journal.pone.0037239.t001
Figure 2. Viability of canine soft tissue sarcoma cells after
LIVP1.1.1 or GLV-1h68 infection at MOIs of 0.1 (A) and 1.0 (B),
respectively. Viable cells after infection were detected using 3-(4, 5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma,
Taufkirchen, Germany). Mean values (n=3) and standard deviations
are shown as percentages of respective controls. The data represent
two independent experiments. There were no significant differences
between groups (P.0.05).
doi:10.1371/journal.pone.0037239.g002
Figure 3. Comparison of the replication capacity of the vaccinia
virus strains GLV-1h68 and LIVP1.1.1 in canine soft tissue
sarcoma cells. For the viral replication assay, STSA-1 cells grown in 24-
well plates were infected with either GLV-1h68 or LIVP1.1.1 at an MOI of
0.1. Cells and supernatants were collected for the determination of virus
titer at various time points. Viral titers were determined as pfu per well
in triplicates by standard plaque assay in CV-1 cell monolayers.
Averages plus standard deviation are plotted. The data represent two
independent experiments. The statistical significance was analyzed
using two-way ANOVA followed Bonferroni post-test on log trans-
formed PFU data. *, **, and *** indicate P,0.05, 0.01, and 0.001,
respectively.
doi:10.1371/journal.pone.0037239.g003
Vaccinia Virus Therapy of Canine Sarcoma
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37239cytocentrifuged at 1000 rpm for 3 min onto charged glass slides.
Subsequently, the adherent cells were incubated for 10 minutes
with BCIP/NBT phosphatase substrate (KPL, Inc., Gaithersburg,
Maryland, USA) to detect alkaline phosphatase (ALP) activity or
were immunostained directly with a murine anti-canine CD18
monoclonal antibody (CA16.3C10, a gift from Dr. Peter Moore,
University of Califorina, Davis, CA, USA). Additional slides were
subjected to antigen retrieval in a decloaking chamber (Biocare
Medical, Concord, CA, USA) and incubated with a cocktail of
murine monoclonal anti-AE1 and anti-AE3 antibodies (Biogenex,
San Ramon, CA, USA) to detect cytokeratin, or with a murine
monoclonal anti-vimentin antibody (V-9, Biogenex).
Following successful cell line establishment, cells were confirmed
to be of canine origin and identity validated through multiplex
species-specific PCR and short tandem repeat analysis, as recently
described [25].
Virus strains
GLV-1h68 is a genetically stable oncolytic virus strain designed
to locate, enter, colonize and destroy cancer cells without harming
healthy tissues or organs [13].
LIVP1.1.1 was derived from LIVP (Lister strain, Institute of
Viral Preparations, Moscow, Russia). The sequence analysis of
LIVP1.1.1 revealed the presence of different mutations in several
genes including that of thymidine kinase (Chen et al manuscript in
preparation). In addition, LIVP1.1.1 demonstrated also different
plaque form morphology in comparison to GLV-1h68 in CV-1
cells.
Cell viability assay
8610
4 cells/well were seeded in 24-well plates (Nunc,
Wiesbaden, Germany). After 24 h in culture, cells were infected
with either LIVP1.1.1 or GLV-1h68 using multiplicities of
infection (MOI) of 0.1 and 1.0. The cells were incubated at
37uC for 1 h, then the infection medium was removed and
subsequently the cells were incubated in fresh growth medium.
The amount of viable cells after infection was measured using 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) (Sigma, Taufkirchen, Germany). At 24, 48, 72, or 96 h
after infection of cells, medium was replaced by 0.5 ml MTT
solution at a concentration of 2.5 mg/ml MTT dissolved in RPMI
1640 without phenol red and incubated for 2 h at 37uCi na5 %
CO2 atmosphere. After removal of the MTT solution, the color
reaction was stopped by adding 1 N HCl diluted in isopropanol.
The optical density was then measured at a wavelength of 570 nm.
Uninfected cells were used as reference and were considered as
100% viable.
Viral replication
For the viral replication assay, cells grown in 24-well plates were
infected with either LIVP1.1.1 or GLV-1h68 at an MOI of 0.1.
After one hour of incubation at 37uC with gentle agitation every
20 min, the infection medium was removed and replaced by a
fresh growth medium. After 1, 6, 24, 48, 72 and 96 hours, the cells
and supernatants were harvested. Following three freeze-thaw
cycles, serial dilutions of the lysates were titered by standard
plaque assays on CV-1 cells. All samples were measured in
triplicate.
Vaccinia virus-mediated therapy of STSA-1 xenografts
Tumors were generated by implanting 1610
6 canine soft tissue
sarcoma cells in 100 ml PBS subcutaneously into the right hind leg
of 6- to 8-week-old female nude mice (NCI/Hsd/Athymic Nude-
Foxn1
nu, Harlan Winkelmann GmbH, Borchen, Germany). On
day 28, a single dose of LIVP1.1.1 or GLV-1h68 virus (1610
7
plaque forming units [pfu] in 100 ml PBS) was injected into the tail
Figure 4. Growth of canine soft tissue sarcoma tumors in virus-
and mock-treated mice. (A) Groups of STSA-1 tumor-bearing nude
mice (n=6) were either treated with a single dose of 1610
7 pfu GLV-
1h68, LIVP1.1.1 or with PBS (mock control). Tumor size was measured
twice a week. Two-way analysis of variance (ANOVA) with Bonferroni
post-test was used for comparison of two corresponding data points
between groups. *, **, and *** indicate P,0.05, 0.01, and 0.001,
respectively. (B) Animals with established STSA-1 flank tumors
(.600 mm
3) were distributed into two experimental groups (n=4 per
group). Flank tumors were treated with injections of a single dose of
LIVP1.1.1 (1610
7 pfu) or PBS alone as control. The statistical significance
was confirmed by Student’s t-test (***p,0.001).
doi:10.1371/journal.pone.0037239.g004
Figure 5. Survival curves of LIVP1.1.1-treated and non-treated
STSA-1 tumor-bearing mice. The comparison of the survival
between the different treatment groups (n=5) was statistically
evaluated by Kaplan-Meier and log-rank (Mantel-Cox) tests (GraphPad
Prism, San Diego, CA). P,0.05 was considered statistically significant. **
P=0.0039.
doi:10.1371/journal.pone.0037239.g005
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with PBS only. Tumor growth was monitored weekly in two
dimensions using a digital caliper. Tumor volume was calculated
as [(length6width
2)/2].
The significance of the results was calculated by two-way
analysis of variance (ANOVA) or Kaplan-Meier and log-rank
(Mantel-Cox) tests (GraphPad Prism software, San Diego, USA) or
Figure 6. Virus distribution in STSA-1 xenografts after 7 (A) and 35 (B) day post injection with GLV -1h68 or LIVP1.1.1. Tumor-bearing
mice were injected with 1610
7 pfu of GLV-1h68 or LIVP1.1.1. Three mice of each group were analyzed at 7 and 35 dpvi for virus distribution. The data
were determined by standard plaque assays on CV-1 cells using aliquots of the homogenized tissue and were displayed as mean pfu/g organ or
tissue (n=3). For each organ, aliquots of 0.1 ml were measured in triplicates (detection limit: 10 pfu/organ or tissue). The values are the mean of
triplicate samples, and the bars indicate SD. Statistical analysis for the tumors was performed using 1-way ANOVA followed by Bonferroni post-test on
log transformed pfu data. There were no significant differences between groups (P.0.05). The study was repeated in two independent experiments.
doi:10.1371/journal.pone.0037239.g006
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tumors at 7 dpvi (n=3)
Marker Ratio
A GLV-1h68/PBS Ratio
A LIVP1.1.1/PBS Positive cells
CD11b 1.3760.43 1.6361.37 granulocytes, macs, NK cells
MHCII 1.4060.75 2.0862.32 B cells, macs, DC
CD19 0.8860.57 2.0160.93 DC, B cells
CD45 1.1660.58 2.1661.60 all leukocytes
F4/80 1.3760.62 2.2263.04 majority of mature macs
Ly6G high 5.3963.76 11.0365.65 neutrophils
CD11c 1.8362.82 2.0362.09 DC, NK cells
CD49b 2.5161.08 3.5765.62 majority of NK and NKT cells
GFP
+ 11.15%66.7% n.a. total GFP-positive cells
GFP
+/MHCII
+ 0.91%60.7% n.a. GFP- and MHCII-positive cells
GFP
+/CD45
+ 1.52%61.2% n.a. GFP- and CD45-positive cells
GFP
+/Ly6G 0.26%60.2% n.a. GFP- and Ly6G high-positive cells
ARatios greater than 1 indicate an increased accumulation of host immune cells in virus-infected tumors.
Abbreviations: macs: macrophages; DC: dendritic cells; NK: natural killer cells; NKT: natural killer T cells; n.a.: not applicable.
doi:10.1371/journal.pone.0037239.t002
Figure 7. Presence of Ly-6G-positive cells (neutrophils) in virus-infected and non-infected STSA-1 xenografts at 7 dpvi. (A, B)
Percentage of Ly-6G-positive cells (neutrophils) in tumors (A) and in peripheral blood (B) of STSA-1 xenografts 7 days after GLV-1h68-, LIVP1.1.1- or
PBS-treatment. Experiments were done twice with at least 3 mice per group. The data are presented as mean values +/2 standard deviations. The
statistical significance was analyzed using two-way ANOVA followed Bonferroni post-test (** P,0.01, *P,0.05). (C) Immunohistochemical staining of
Ly-6G-positive cells (neutrophils). Cryosections (10 mm-thick) of tumors were labeled with anti-Ly-6G antibody specfic for neutrophil granulocytes
(red). In addition, bright-field transmission images (BF) and overlays of Ly-6G signals and transmission images (bright-field) are shown. Scale bars,
3 mm.
doi:10.1371/journal.pone.0037239.g007
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deviation). P values of ,0.05 were considered significant.
Histological analysis of tumors
The spontaneous canine tumor surgically removed from a
patient at the University of Illinois Veterinary Teaching Hospital
was submitted to the University of Illinois Veterinary Diagnostic
Laboratory (VDL) for histopathologic analysis. Portions of the
tissues were paraffin-embedded, sectioned and stained with
hematoxylin and eosin (H&E) to identify the tumor type.
For histological studies of xenograft model, tumors were excised
and snap-frozen in liquid N2, followed by fixation in 4%
paraformaldehyde/PBS at pH 7.4 for 16 h at 4uC. Tissue samples
were sectioned (10 mm thickness) with the cryostat 2800 Frigocut
(Leica Microsystems GmbH, Wetzlar, Germany). After dehydra-
tion in 10% and 30% sucrose (Carl Roth, Karlsruhe, Germany)
specimens were embedded in Tissue-TekH O.C.T. (Sakura Finetek
Europe B.V., Alphen aan den Rijn, Netherlands).
Endothelial blood vessel cells were stained with a hamster
monoclonal anti-CD31 antibody (Chemicon International, Teme-
cula, USA; MAB1398Z). Anti-Mouse Ly-6G (eBioscience, San
Diego, USA; 14-5931-81) was used to stain neutrophil granulo-
cytes. DyLight549- and DyLight649-conjugated secondary anti-
bodies (donkey) were obtained from Jackson ImmunoResearch
(Pennsylvania, USA).
A part of tissue sectioning was performed as described by [26].
In this case, VACVs were labeled using polyclonal rabbit anti-
vaccinia virus (anti-VACV) antibody (Abcam, Cambridge, UK),
which was stained using Cy3-conjugated donkey anti-rabbit
secondary antibodies obtained from Jackson ImmunoResearch
(West Grove, PA, USA).
Immune cells were labeled using rat anti-mouse MHCII
antibody detecting a polymorphic determinant present on B cells,
monocytes, macrophages and dendritic cells (eBioscience, San
Diego, CA) and Cy5-conjugated secondary antibodies (donkey)
obtained from Jackson ImmunoResearch (West Grove, PA, USA).
The fluorescence-labeled preparations were examined using the
MZ16 FA Stereo-Fluorescence microscope (Leica) equipped with
the digital DC500 CCD camera and the Leica IM1000 4.0
software (130061030 pixel RGB-color images). Digital images
were processed with Photoshop 7.0 (Adobe Systems, Mountain
View, CA, USA).
Measurement of blood vessel density and fluorescence
intensity of the CD31 signal in the tumor tissue
Blood vessel density was measured in digital images (6100
magnification) of CD31-labelled 10-mm-thick tumor cross-sections
using Leica IM1000 4.0 software. Eighteen images per tumor were
analyzed per staining (3 tumors per group, 3 sections of each
tumor and 6 images per section). Exposure time for individual
images was adjusted to ensure clear visibility of all detectable blood
vessels and decorated with 6 equidistant horizontal lines using
Photoshop 7.0. All blood vessels crossing these lines were counted
to obtain the vessel density per section.
Fluorescence intensity of the CD31-labelling in 10-mm-thick
sections of control tumors and infected areas of virus-colonized
tumors was measured on digital images (6100 magnification) of
specimens stained for CD31 immunoreactivity. On the fluores-
cence microscope, the background fluorescence was set to a barely
detectable level by adjusting the gain of the CCD camera before
all the images were captured with identical settings. RGB-images
were converted into 8-bit gray scale images (intensity range 0–255)
using Photoshop 7.0. The fluorescence intensity of the CD31-
labelling represented the average brightness of all vessel-related
pixels and was measured using Image J software http://rsbweb.
nih.gov/ij.
Flow cytometric (FACS) analysis
For flow cytometric analysis, three or four mice from each
group were sacrificed by CO2 inhalation and the tumors were
removed. The tumor tissues were minced and incubated
individually in 10.000 CDU/ml Collagenase I (Sigma, Steinheim,
Germany) and 5 MU/ml DNase I (Calbiochem, Darmstadt,
Germany) for 75 min at 37uC and then passed through a 70-mm
nylon mesh filter (BD Biosciences, Erembodegem, Belgium).
Figure 8. Determination of vascular density using CD31
immunohistochemistry in virus- treated and non-treated
tumors at 7 dpvi. (A) Blood vessel density in STSA-1 tumors The
vascular density was measured in CD31-labeled tumor cross-sections
(n=3 mice per group) and presented as mean values +/2 standard
deviations. The study was repeated in an independent experiment.
There were no significant differences between groups (P.0.05,
Student’s t-test). (B) Fluorescence intensity of the CD31 signal
of blood vessels. The fluorescence intensity of the CD31-labelling
represented the average brightness of all vessel-related pixels and
determined as described by [32]. The fluorescence signal was measured
in 18 images of each tumor (n=3 mice per group). Shown are the mean
values +/2 standard deviations. The study was repeated in an
independent experiment. (*** P,0.001, **P,0.01, Student’s t-test)
doi:10.1371/journal.pone.0037239.g008
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with 0.5 mg of anti-mouse CD16/32 antibody (clone 93,
Biolegend, San Diego, USA) per one million cells for 20 min on
ice. After that, the cells were incubated at 4uC for 10 min in PBS
with 2% FCS in the presence of appropriate dilutions of labeled
monoclonal antibodies: anti-mouse MHCII-PE (Clone M5,
eBioscience, San Diego, CA, USA), anti-CD11b-PerCPCy5.5
(Clone M1/70, eBioscience), anti-CD11c-APC (Clone N418,
BioLegend, San Diego, USA), anti-CD49b-APC (Clone DX5,
BioLegend), anti-CD19-PerCP-Cy5.5 (Clone 6D5, BioLegend),
anti-F4/80-APC (Clone BM8, eBioscience), anti-Ly-6G-PE (Clone
1A8, BD Biosciences) and anti-CD45-PerCP (Clone 30-F11, BD
Biosciences).
Numbers of neutrophils in tumors and peripheral blood of
STSA1-tumor-bearing mice were determined in parallel by
staining with APC-eFluor 780-conjugated mAbs to Ly-6G (Clone
RB6-8C5 eBioscience, San Diego, CA, USA). Before specific Ab
staining, cells were incubated with Fc blocker (anti-CD16/CD32
mAb) for 20 min.
Stained cells were subsequently analyzed, using an Accuri C6
Cytometer and FACS analysis software CFlow Version 1.0.227.4
(Accuri Cytometers, Inc. Ann Arbor, MI USA).
Results
Histological and pathological examination of original
canine tumor and xenograft tumors
The histological examination of the original primary tumor
revealed atypical mesenchymal cells haphazardly arranged in
bundles and streams (Fig. 1A). The cells had a moderate amount
of eosinophilic cytoplasm and oval nuclei with coarse, clumped
chromatin and one to two prominent nucleoli. Moderate
anisocytosis and anisokaryosis were noted. There were one to
two mitotic figures per 6400 magnification. Neoplastic cells
extended into adjacent muscle and areas of compacted collagen.
The mass was diagnosed as a low grade II soft tissue sarcoma with
narrow surgical margins. In addition, aliquots of canine cell
explants from the tumor (in following termed as STSA-1) were
analysed by cytochemical staining as described above (Fig. 1B,
Table 1 and Figure S1). Alkaline phosphatase (ALP) activity is
detectable in cells derived from bone, liver, kidney and intestine;
CD18 is a marker for histiocytic cells; cytokeratin is found within
cells of epithelial origin; and vimentin is present in mesenchymal
cells. Cells were positive for vimentin, but negative for other
proteins, which supports the soft tissue sarcoma diagnosis (Table 1
and Figure S1). The canine origin of STSA-1 cells was also
confirmed through multiplex species-specific microsatellite PCR
(Figure S2).
Figure 9. Immunohistochemical staining of infected and uninfected STSA-1 xenograft tumors at 21 dpvi. Tumor-bearing mice were
either mock treated (PBS) or infected with GLV-1h68 or LIVP1.1.1. Tumor sections were labeled either with anti-vaccinia virus (VACV, grey) or anti-
MHCII antibodies (red). GLV-1h68 infection and/or phagocytosis was indicated by GFP fluorescence (green). In addition, bright-field transmission
images (BF) of all tumor sections are shown. Scale bars, 2.5 mm.
doi:10.1371/journal.pone.0037239.g009
Figure 10. Histological analysis of LIVP1.1.1-infected (A) and
non-infected (B) STSA-1 xenograft tumors, 21 dpvi (H&E, bars,
100 mm). Necrotic area is marked by arrows.
doi:10.1371/journal.pone.0037239.g010
Vaccinia Virus Therapy of Canine Sarcoma
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37239To analyze the tumorigenic potential of the new isolated cell
line STSA-1, 1610
6 cells were implanted into the right hind leg of
6- to 8-week-old female nude mice. Ninety-six percent (58 from
60) of the STSA-1-implanted mice developed a detectable tumor
mass. Seven to nine weeks post implantation, most mice developed
tumors with volumes of 2500 to 3000 mm
3. None of these mice
showed any signs of metastasis or of invasive growth pathologi-
cally. Histological analysis of the tumors revealed a population of
cells with numerous signs of malignancy including mitotic figures,
anisokaryosis, anisocytosis, binucleation and multinucleation
(Fig. 1C). In cell culture STSA-1 cells are spindle-shaped with
long extensions and do not form closed monolayers (Fig. 1D).
The data demonstrated that the STSA-1 cell line is highly
tumourigenic in female nude mice and also mimicked the behavior
of a soft tissue sarcoma.
Analysis of the oncolytic potential of VACV strains
against canine sarcoma cells in culture
STSA-1 cells were seeded three days prior to infection in 24-
well plates. Cells were then infected with either LIVP1.1.1 or
GLV-1h68 at MOIs of 1.0 and 0.1, respectively. Cell viability was
analyzed at 24, 48, 72 and 96 hours post-virus-infection (hpvi) by
MTT-assays (Fig. 2). The data demonstrated that both VACV
strains efficiently infected and destroyed cells of the canine soft
tissue sarcoma line STSA-1 under cell culture conditions.
Although there was no statistically significant difference in
number of viable cells between the two virus strains, these results
indicated that LIVP1.1.1 virus infection led to a somewhat more
efficient eradication of the canine sarcoma cells in culture
compared to GLV-1h68- treatment.
Efficacy of LIVP1.1.1- and GLV-1h68-replication in STSA-1
cells
STSA-1 cells were infected with either LIVP1.1.1 or GLV-1h68
at a MOI of 0.1. Standard plaque assay was performed for all
samples to determine the viral titers at different time points during
the course of infection (Fig. 3). The maximum viral titers (total) of
each virus were determined for LIVP1.1.1 (4.54610
6 pfu/well) at
48 hpvi and for GLV-1h68 (2.55610
6 pfu/well) at 72 hpvi. In
addition, we found significant differences from titers of LIVP1.1.1
compared with GLV-1h68 at 24 hpvi (***P,0.001) and 48 hpvi
(**P,0.01) as well as at 96 hpvi (*P,0.05).
These data demonstrated that LIVP1.1.1 can replicate more
efficiently than GLV-1h68 in STSA-1 cells under these experi-
mental conditions.
Oncolytic effect of a single systemic application of VACVs
on STSA-1 xenografts
Eighteen female nude mice at an age of 6–8 weeks were
implanted with 1610
6 STSA-1 cells. Four weeks post implanta-
tion, all mice developed tumors with volumes of 400 to 500 mm
3.
Animals were separated into three groups (n=6) and were injected
with a single dose of GLV-1h68, LIPV1.1.1 (1610
7 pfu in 100 ml
PBS) or PBS (100 ml) intravenously (i.v.) into the lateral tail vein.
Tumor size was measured twice a week. As shown in Fig. 4A, the
virus treatment led to a significant difference (***P,0.001) in
tumor growth between PBS controls and all virus-treated mice on
21 and 25 days post-virus-injection (dpvi). Due to excessive tumor
burden (.3000 mm
3), all animals of the control group were
euthanized after 25 dpvi. In addition, at 42 dpvi we determined a
significant difference (**P,0.01) between GLV-1h68 vs
LIVP1.1.1. Moreover, two of six mice of the GLV-1h68-treated
group developed tumors with volumes greater than 3000 mm
3 and
had to be euthanized after 42 dpvi.
These data indicated that LIVP1.1.1 had a higher oncolytic
potential than GLV-1h68 against canine soft tissue sarcoma
xenografts.
To determine whether the initial tumor size at the time of virus
delivery would affect the outcome of virotherapy, we started a
second therapeutic experiment in which the average starting
tumor volume before injection was 40% larger compared to that of
the corresponding LIVP1.1.1-group in the experiment described
before (see Fig. 4A). In this experimental setting, a single i.v.
injection of LIVP1.1.1 into mice bearing canine soft tissue
sarcoma STSA-1 xenografts led to near-complete tumor regres-
sion over a 42-day period without toxicity (Fig. 4B). These data
could be evidence, that larger STSA-1-tumors (600 to 1000 mm
3)
are more responsive to LIVP1.1.1-treatment than smaller STSA-
1-tumors under these experimental conditions.
In a third independent therapeutic experiment we analyzed the
long-term survival of LIVP1.1.1-treated mice compared to PBS-
treated control mice (Fig. 5). Here, the mice of the untreated group
were euthanized at day 17 (n=1) and day 24 (n=4), due to the
development of tumors with volumes greater than 3000 mm
3.I n
the virus-treated group, two animals were found dead at 39 and
58 dpvi, respectively (no pathological changes were observed). The
remaining three animals of this group were euthanized under
certain criteria, 30% weight loss (n=2; at days 48 and 98) and
tumor greater volume than 3000 mm
3 (n=1; at day 105).
In summary, this experiment demonstrated that a single
injection with LIVP1.1.1 vaccinia virus led to significantly longer
survival (**P=0.0039) of the treated mice compared to the non-
treated animals.
Comparison of LIVP1.1.1 and GLV-1h68 distribution in
tumor-bearing nude mice
In order to analyze the reason for different oncolytic effects of
VACV strains in STSA-1 xenografts we first compared the virus
colonization and distribution pattern of the virus strains in vivo at
early and late time points after virus treatment. Figure 6
summarizes the virus distribution data in sarcoma tumor-bearing
nude mice after i.v. injection of VACV strains at a single dose of
1610
7 pfu per mouse. At 7 dpvi the highest viral titers were
identified in primary tumors of virus-treated mice (Fig. 6A). In the
tumor tissues, there was no significant difference of the virus titers
between LIVP1.1.1- and GLV-1h68-injected groups. At the same
time point, we also found plaque forming units in some organs of
mice injected with LIVP1.1.1 but not with GLV-1h68 (Fig. 6A).
Interestingly, a few GLV-1h68 virus particles were detected in
liver, lung and spleen on 35 dpvi (Fig. 6B). However, we found
about 10
4–10
5 fold more pfus of GLV-1h68 in tumors in
comparison to healthy tissues (lung, spleen, skin) at this time point
(Fig. 6B).
Taken together, our data clearly demonstrated that both viruses
GLV-1h68 and LIVP1.1.1 display an enhanced tumor specific
replication in STSA-1 xenograft mice.
Analysis of host immune response and the tumor
vascularization in the early-phase (before 7 dpvi) of virus
infection
For an investigation of the potential anti-tumor mechanism, we
analyzed the virus interactions with cells of the host immune
system in the early-phase (before 7 dpvi) of virus infection. Tumor
single cell suspensions derived from infected and uninfected
STSA-1 tumors were analyzed by flow cytometry for the presence
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CD11b-, MHCII-, CD19-, CD45-, F4/80-, Ly6G high, CD11c-
and CD49b-positive immune cells were higher in cell suspensions
derived from virus-infected tumors compared to that from
uninfected controls (Table 2; ratios greater than 1). In addition,
at 7 dpvi approximately 0.9% of the MHCII-positive, 1.5% of the
CD45-positive and 0.26% Ly6G high
+ cells were GFP-positive in
GLV-1h68-infected tumors, indicating that either these immune
cells were infected with vaccinia virus or they phagocytized virus-
infected tumor cells. In this experimental setting, approximately 5-
and 11-fold higher numbers of Ly6G high
+ cells (neutrophils) were
found in GLV-1h68- and LIVP1.1.1–infected tumors than in
uninfected tumors, respectively (Table 2).
Since, it is known that neutrophils are one of the first cell types
recruited to the sites of infections [27], we used these cells as
markers for monitoring of viral infection on systemic level and in
the tumor tissue. A parallel flow cytometric analysis of neutrophils
was performed on peripheral blood and tumor samples. As shown
in Fig. 7A there was approximately 6.6–42.1 fold higher
accumulation of neutrophils in the LIVP1.1.1-treated tumors
compared to GLV-1h68- and PBS-treated tumors (**P=0.0075;
**P=0.0026), respectively. The significantly increased accumula-
tion of neutrophils in tumors did not coincide with any reduction
in peripheral blood neutrophils (Fig. 7B). An additional immuno-
histochemical examination confirmed the increased accumulation
of neutrophils in LIVP1.1.1–infected tumors as compared to
GLV-1h68-infected tumors (Fig. 7C). On the other hand, in a
previous experiment, there was no significant difference of the
virus titers between LIVP1.1.1- and GLV-1h68-infected tumors
(Fig. 6A).
To assess the impact of viral tumor colonization on the tumor
vasculature, we analyzed the CD31-positive vascular network in
tissue sections of the same tumors by fluorescence microscopy. In
this context, CD31-labelled cross sections of control (PBS),
LIPV1.1. 1- and GLV-1h68-colonized tumors were used for
determination of the vascular density (Fig. 8A). The data revealed
that there was no significant difference in the vascular density
between the three analyzed groups (Fig. 8A). In addition,
fluorescence intensity of the CD31 signal of blood vessels was
measured (Fig. 8B). The results revealed that the fluorescence
intensity of all vessel-related pixels of both virus-infected tumors
were significantly increased in comparison to PBS-injected control
tumors (PBS vs. LIVP1.1.1 *** P=0.00021; PBS vs. GLV-1h68
**P=0.008). This means that the virus colonization led to an up-
regulation of CD31 protein, which mediates transendothelial
migration of immune cells to sites of infection. In this experimental
setting, however, there was no significant difference between the
fluorescence intensity of vessel-related pixels of LIPV1.1.1- and
GLV-1h68-tumors (P=0.0351).
Presence of virus and host immune cells in VACVs-
infected and non-infected STSA-1 tumors at a late phase
of infection
By immunohistolchemistry we analyzed tissue sections of
primary tumors of STSA-1 tumor bearing mice injected with
LIVP1.1.1, GLV-1h68 or PBS at 21 dpvi (Fig. 9). There was no
significant difference in viral distribution of the two different virus
strains at this stage of infection (Fig. 9, panel 2, grey color). The
histological data revealed also that MHC class II-expressing host
cells including B cells, macrophages and dendritic cells were
present in the uninfected tumors. The single injection with
LIVP1.1.1 or GLV-1h68 led to similar specific intratumoral
infiltration of these host cells in the tumor tissue (Fig. 9). In
summary, the results suggest that the number of the MHCII-
positive immune cells in the late phase of infection is not crucial for
the better oncolytic effect of LIVP1.1.1 compared to GLV-1h68 in
STSA-1 xenografts.
In addition, portions of the xenograft tumor tissues were
paraffin-embedded, sectioned, and stained with hematoxylin and
eosin (H&E) to identify possible differences between LIVP1.1.1
virus-treated (Fig. 10A) and non-treated tumors (Fig. 10B). Indeed,
the virus-treated tumors looked inflamed (mixed population of
neutrophils, lymphocytes and macrophages), a significant portion
of the typical streaming and bundling structure of the tumor mass
was disrupted and the main part of the tumor was necrotic.
Discussion
Several oncolytic viruses including adenovirus strains CAV-1
and CAV-2 [28], canine distemper virus [29] and vaccinia virus
strain GLV-1h68 [22,23] have been used for canine cancer
therapy in preclinical studies [30,31]. However, in contrast to
human studies, clinical trials with oncolytic viruses for canine
cancer patients have not been reported.
In this study, we investigated the oncolytic efficiency of two
vaccinia virus strains GLV-1h68 and LIVP1.1.1, against a new
canine soft tissue sarcoma cell line in culture and in a xenograft
model. The results showed that both VAVCs tested were able to
effectively infect, replicate in and lyse canine soft tissue sarcoma
cells in culture. In addition, our data revealed that the cell line
STSA-1 is highly tumorigenic in nude mice. Local tumor growth
occurred in 96% of the animals that had received 1610
6 cells
subcutaneously. Interestingly, none of the control STSA-1
xenografts showed any signs of metastasis. Because the donor
had evidence of lymphatic metastasis, we conclude that time for
metastasis formation exceeds the time limitation owed to local
tumor growth in mice. Moreover, we observed histological
similarities between xenografts in mice and the pattern of the
original tumor in the dog (Fig. 1). In addition, we found same
indirect evidence for metastases formation in virus-treated STSA-1
mice (see later discussion). Taken together, the described xenograft
model could be extremely useful as an in vivo tool for preclinical
studies against canine soft tissue sarcoma.
The current study also demonstrated the suitability of
LIVP1.1.1 and GLV-1h68, to achieve a significant inhibition of
tumor growth and damage of tumor tissues in the tumor-bearing
mice when compared to PBS controls. We also found that
LIVP1.1.1 had a higher oncolytic potential than GLV-1h68 in
these experimental settings. To clarify the reason for these
differences we investigated the mechanisms by which oncolytic
viruses destroy the STSA-1 tumors under these experimental
conditions. Generally, it is believed that an oncolytic vaccinia virus
destroys tumors by direct viral oncolysis of tumor cells [32,33], by
destruction of the tumor vasculature [34] and by induction of host
antitumoral immune responses [35], or most likely, a combination
of these mechanisms [18,19].
Therefore, we first analyzed the direct viral oncolysis of STSA-1
tumor cells by examination of the virus colonization and
distribution pattern of the two virus strains in vivo. The highest
viral titers were identified in primary tumors of virus-treated mice
(Fig. 6) at days 7 and 35 post virus injection. However, there was
no significant difference of the tumor titers between the two viruses
tested. In contrast, at 7 dpvi we also detected plaque forming units
in some organs of mice injected with LIVP1.1.1 only. This fact
could be evidence that the LIVP1.1.1 was either less tumor-
specific or more virulent in mice compared to GLV-1h68.
Surprisingly, GLV-1h68 was detected in liver, lung and spleen
on 35 dpvi (Fig. 6B). In this case, the later presence of GLV-1h68
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Moreover, we have demonstrated that GLV-1h68 is a highly
tumor- and metastases-selective [20,36]. It could also be possible
that due to leakiness of blood vessels in solid tumors, circulating
virus-infected tumor cells or cell particles may end up in healthy
tissues such as the lung, liver and spleen. However, the reason for
presence of a few pfus of GLV-1h68 in some organs on 35 dpvi is
currently unknown.
In summary, the differences of virus distribution after injection
withGLV-1h68orLIVP1.1.1inSTSA-1xenograftsalonecouldnot
satisfactorily explain the different oncolytic effects of these strains.
Our survival experiment revealed a significantly longer survival
(P=0.0039) of the LIVP1.1.1-treated mice compared to the PBS-
treated animals. For a potential optimization of our therapeutic
protocol for canine patients, an additional virus injection or
combination with standard anti-cancer therapies such as chemo-
therapy, like demonstrated by [18,37], are currently under
investigation.
To identify other factors responsible for better oncolytic effects
of LIVP1.1.1 in STSA-1 xenografts, we investigated the virus
interactions with the components of the tumor microenvironment,
such as tumor vasculature and the cells of the host immune system.
The tumor vasculature is an important part of the tumor
microenvironment supporting tumor growth by delivery of
nutrients, oxygen and immune cells. Therefore, the destruction
of the vascular network in tumors may be a potential therapeutic
strategy for cancer therapy. In the STSA-1 xenografts model, the
vascular density of tumors was not significantly changed between
the GVL-1h68, LIVP1.1.1 and PBS (control) groups at 7 dpvi
(Fig. 8A). In contrast, significantly increased CD31 expression in
the tumor vasculature was observed at the same day after virus
infection with LIPV1.1.1 and GLV-1h68 (Fig. 8B). The activated
endothelium that is characterized by vascular hyperpermeability
could also be one additional reason for significantly increased
accumulation of host immune cells in these virus-injected tumors
compared to control PBS-tumors. A similar effect on tumor
vasculature was found in human breast tumor xenografts upon
colonization with GLV-1h68 [32].
In the last part of our study, we investigated the virus interactions
withthecellsofhostimmunesystem.Inthiscontext,weanalyzedthe
immunological host response in the early-phase (7 dpvi) of virus
infection. Our flow cytometry data demonstrated a specific
intratumoral infiltration of host immune cells and especially
neutrophils (Ly6G high positive cells) in virus-injected STSA-1
mice after 7 dpvi (Table 2). In order to confirm these data, we have
analyzed in parallel the distribution of neutrophils in tumors and
peripheral blood of virus-infected and uninfected STSA-1 xeno-
grafts (Fig. 7). These experiments again revealed significantly
enhanced numbers of neutrophils in tumors of virus-injected mice
but not in the peripheral blood at 7 dpvi (Fig. 7). In addition, the
number of neutrophils in LIVP1.1.1 infected tumors was signifi-
cantly higher than that in GLV-1h68 tumors. On the basis of these
data, we assume that the stronger anti-tumor effect of LIVP1.1.1 in
comparison to GLV-1h68 could be dependent on the increased
number of neutrophils in the tumor bed. Several other groups have
reported that virotherapy induces massive tumoral infiltration of
neutrophils, which may be part of virotherapy-mediated antitumor
mechanism [34,38]. In this context, Breitbach and colleagues
postulated that massive neutrophil activation followed by vascular
damage and apoptosis of uninfected tumor cells one day after
infection are the main cause of tumor cell destruction [34].
However,itisknown,thatthetumor-associated neutrophils(TANs)
may be associated with both pro- and anti-tumoral activities (for
reviews, see [27,39]). Recently, after a SM16 therapy, Fridlender
andcolleagueshaveidentifiedtwodifferentpopulations(N1andN2)
of TANs, typical TANs (N2) that promote tumor growth and
cytotoxic TANs (N1) capable of killing tumor cells [40]. In our
STSA-1 model, the significantly enhanced intratumoral accumula-
tion of neutrophils was not associated with significantly reduced
vascular density in primary tumors. In these experimental settings,
we found evidence for direct interactions between vaccinia virus or
virus-infected cells and neutrophils in the tumor tissue (Table 2;
GFP-positive cells). Therefore we speculated that high number of
the virus-activated neutrophils (‘‘N1-like’’) could be cytotoxic in the
tumorbyprovidingoffreeoxygenradicalsandproteinasesingreater
concentrations than typicalnon-activated TANs.Thiscould be also
an explanation for the better oncolytic effect of LIVP1.1.1 strain.
Taken together, however, the anti-tumor effect of virus-
activated neutrophils in the virotherapy could be dependent on
type and origin of tumors, stage of tumor development, virus strain
or host studied, but finally on the balance between antiviral and
antitumoral immune responses.
Our findings suggest that the virotherapy-mediated anti-tumor
mechanism in STSA-1 xenografts could be a combination of the
direct viral oncolysis of tumor cells and the virus-dependent
activation of tumor-associated host immune cells, mainly neutro-
phils.
In summary, therapy with the vaccinia strains and especial
LIVP1.1.1 demonstrated outstanding anti-tumor activity in canine
soft tissue sarcoma cells and in the STSA-1 xenograft model.
Therefore we propose that the LIVP1.1.1 vaccinia virus strain
may be useful for the treatment of spontaneous soft-tissue
sarcomas in dogs.
Supporting Information
Figure S1 Cytocentrifuged STSA-1 cells magnification
6500. (A) Wright-Giemsa stain, (B) vimentin, (C) ALP
activity, (D) CD18, (E) cytokeratin. Brown coloration is
indicative of positive staining. Negatively staining samples were
counterstained with Wright-Giemsa stain to visualize cells. All
positive and negative controls stained adequately (data not shown).
(TIF)
Figure S2 Short tandem repeat (STR) analysis of STSA-1
cells. The validation of the cell line was preformed as recently
described [25].The STK kit (StockMarks for Dogs: Canine
Genotyping Kit, Applied Biosystems, Foster City, CA) tested 10
different loci (A): PEZ 1, FHC 2054, FHC 2010; (B) PEZ 5, PEZ
20; PEZ 12; (C) PEZ 3, PEZ 6, PEZ 8, FHC 2079.The observed
allele sizes were typical for canine cells.
(TIF)
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